Stablepharma Team expands to progress development of the World’s First Fridge-free Tetanus diphtheria vaccine

Stablepharma Ltd is delighted to announce two new members who will join the Advisory Board with immediate effect – Richard Lane, an experienced corporate lawyer and Dr Ceri Morgan, Senior Advisor & NED, specialising in capital raises & IPOs within the pharmaceutical sector.

Both Richard and Ceri join the company at an exciting time as Stablepharma Ltd progress towards launching its first commercial fridge-free vaccine for the prevention and treatment of Tetanus Diphtheria (SPVX02). In addition, the company is about to launch a pre-IPO/Series B fund raise in the last quarter of 2023 to move forward with their vaccine candidate SPVX02.

“This is excellent news for Stablepharma as we continue to attract senior industry specialists to our Advisory Board. Both Ceri and Richard bring specific expertise and skills that will support us in achieving our vision of making fridge-free vaccines a reality’, said Özgür Tuncer, CEO & Executive Director. ‘As we know, there are vast challenges within the global cold chain which hinder the efficient distribution and storage of vaccine products’. ‘Worldwide, 75 million women and their babies remain unprotected against maternal and neonatal tetanus₁ – this is only one of the many distressing statistics that we would like to see impacted through our fridge-free technology”.

Richard, a partner at Farrer & Co, is known for his commercial approach to advising corporates in matters of fundraising, mergers and acquisitions. He has considerable expertise in advising established businesses looking to accelerate their growth with second or third round funding. “This is a great opportunity to be part of the Stablepharma journey to make fridge-free vaccines a reality’, said Richard. ‘The story is robust on both the commercial and humanitarian aspects which makes my Advisory Board position very interesting’.

Ceri has an extensive knowledge of the healthcare industry and has been awarded top ranked Extel ratings throughout her career. As Strategic Advisor, she helped build two leading Healthcare and Life science investment banking franchises. Ceri has also worked with several organisations advising Boards on IPO strategy and primary capital raises.

“I have come across many interesting companies over the years, but the best ones are those that take on an insurmountable and fundamental problem and make it happen’. ‘The global impact that Stablepharma will make, is exciting and meaningful”, said Ceri.

“Dr Ceri Morgan and Richard Lane are significant additions to our Advisory Board as the business continues to grow’, said Nick Child, VP & Co-Founder of Stablepharma. ‘We have been working with Richard for several years now and have always been impressed with his knowledge and management style during important negotiations’. ‘It’s great to see two such highly experienced individuals join the team as we accelerate our technology across other candidate vaccines”.

Stablepharma’s R&D team have identified up to 60 vaccine candidates that could be suitable for StablevaX™ technology. By eliminating the need for cold-chain transportation, distribution and storage, StablevaX™ will dramatically increase the availability of existing and new vaccines to patient populations globally.

Stablepharma has in place a manufacturing agreement with Thermo Fisher Scientific [NYSE:TMO] for the GMP manufacture of SPVX02. Stablepharma’s technology platform, StablevaX™ converts existing approved vaccines to fridge-free status. By creating pre-dosed and stable vaccines, it ensures safe, efficient and waste-free delivery without the need for the cold chain.
There are currently no fridge-free vaccine solutions on the marketplace.

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments